The Pharmasyntez company’s generic antitumor drug containing eribulin has been assigned a maximum selling price by the Federal Antimonopoly Service. This means that now you can purchase a 2 ml bottle for just 15,097 rubles, compared to the registered price of 23,794 rubles for the reference drug “Halaven” from Eisai.
Thus, the price of a generic drug is reduced by 36% relative to the cost of a foreign-made reference product. Furthermore, it is stipulated by law that upon the registration of the price for the second domestic generic, the registered prices for the first, specifically Eribulin-Promomed in this instance, must undergo a reduction of more than 13%. The agency will send a corresponding notification to the pharmaceutical manufacturer.
